

IN THE CLAIMSRECEIVED HUBR-1183.1-Div
CENTRAL FAX CENTER

AUG 17 2006

Claims 1-17 (canceled)

18. (currently amended): A stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which can be degraded to 3-deazaadenosine ~~in the~~ in a body under physiological conditions.

19. (previously presented): The stent of claim 18, wherein said analog of deazaadenosine is selected from the group consisting of 3-deazaadenosine-3'-monophosphoric acid, 3-deazaadenosine-3'5'-cyclophosphate and 3-deazaadenosine-5'-diphosphoric acid.

20. (previously presented): The stent of claim 18, wherein said 3-deazaadenosine or analog of 3-deazaadenosine is covalently bound to the stent.

21. (previously presented) A method of preventing in-stent restenosis, or a reperfusion injury or treating and preventing an infectious or an inflammatory coronary syndrome, dilated cardiomyopathy, viral myocarditis or an infection by a parasite that causes in-stent restenosis, a reperfusion injury or an infectious or inflammatory coronary syndrome comprising implanting the stent of claim 18 in a patient in need thereof.

22. (previously presented): The method of claim 21, wherein in-stent restenosis is prevented.

Claims 23-25 (canceled)

26. (previously presented) The stent of claim 18, wherein said analog of deazaadenosine is

3-deazaadenosine-3'-monophosphoric acid.

27. (previously presented) The stent of claim 18, wherein said analog of deazaadenosine is

3-deazaadenosine-3'5'-cyclophosphate.

28. (previously presented): The stent of claim 18, wherein said analog of deazaadenosine is

HUBR-1183.1-Div

3-deazaadenosine-5'-diphosphoric acid.

29. (previously presented) The stent of claim 26, wherein said analog is covalently bound to the stent.

30. (previously presented) The stent of claim 27, wherein said analog is covalently bound to the stent.

31. (previously presented) The stent of claim 28, wherein said analog is covalently bound to the stent.

32. (previously presented) A method of preventing reperfusion injuries comprising implanting the stent of claim 18 in a patient in need thereof.

33. (previously presented) A method of treating an infectious coronary syndrome comprising implanting the stent of claim 18 in a patient in need thereof.

34. (previously presented) A preventing an infectious coronary syndrome comprising implanting the stent of claim 18 in a patient in need thereof.

35. (previously presented) A method of treating an inflammatory coronary syndrome comprising implanting the stent of claim 18 in a patient in need thereof.

36. (previously presented) A method of preventing an inflammatory coronary syndrome comprising implanting the stent of claim 18 in a patient in need thereof.

37. (previously presented) A method of treating dilated cardiomyopathy comprising implanting the stent of claim 18 in a patient in need thereof.

38. (previously presented) A method of preventing dilated cardiomyopathy comprising implanting the stent of claim 18 in a patient in need thereof.

39. (previously presented) A method of treating viral myocarditis by implanting the stent of claim 18 in a patient in need thereof.

40. (previously presented) A method of preventing viral myocarditis by implanting the stent of claim 18 in a patient in need thereof.

41. (previously presented) A method according to claim 21, wherein the method comprises treating in-stent restenosis, a reperfusion injury, an inflammatory coronary syndrome,

HUBR-1183.1-Div
dilated cardiomyopathy, viral myocarditis or an infection by a parasite, that causes in stent restenosis, a reperfusion injury, or an inflammatory coronary syndrome.

42. (previously presented) A method according to claim 21, wherein the method comprises preventing in-stent restenosis, a reperfusion injury, an inflammatory coronary syndrome, dilated cardiomyopathy, viral myocarditis or an infection by a parasite that causes in stent restenosis, a reperfusion injury, or an inflammatory coronary syndrome.

43. (previously presented) The method of claim 41, wherein said parasite is *Maloria tropica*.

44. (previously presented) The method of claim 42, wherein said parasite is *Maloria tropica*.